Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Allogeneic, CAR-T, CD123, Dual/triple agonist Oct 19 | 2023CB-012's IND Cleared by the FDA; Caribou Joins the AML RaceAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Oct 18 | 2023Carvykti's Revenue Continues to Increase; CARTITUDE-6 Starts Recruitment; JNJ’s Q3 2023 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19, Dual/triple agonist Oct 17 | 2023Gilead to Initiate Trial to Evaluate New KITE-197 Asset in LBCL; AstraZeneca to Start Clinical Development of AZD5851 in HCC patientsAccess Free Blast
Free
Posted in: Autologous, CAR-T Oct 12 | 2023Cellares and BMS Extend Collaboration to Include a Second CAR-T Asset; Kristin Yarema Appointed as Poseida’s CEO Replacing Mark GergenAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Oct 09 | 2023No Cell Therapy-Related Updates in October’s CHMP AgendaAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Oct 03 | 2023You May Have Missed: Gilead Terminates 2 Arms in ZUMA-25 Trial; UPenn Starts Trial in Prostate Cancer with Former Tmunity Asset; A2 Bio Publishes New Study in Solid Tumors; Cartesian to Initiate Trial in SLEAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Sep 27 | 2023GC012F Achieves 100% sCR in Chinese IIT for NDMM; First R/R MM Patient Dosed with GC012F in the US; AbbVie Terminates Agreement with CaribouAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T Sep 22 | 2023AMT Designation Program and CDRP Pilot to Facilitate CMC Development of Products; ASGCT 2023 Policy Summit Analysis (Blast 2/2)Access Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T Sep 22 | 2023The Office of Therapeutic Products Bets on Communication; New Cell and Gene Therapy Access Model to Be Tested; ASGCT 2023 Policy Summit Analysis (Blast 1/2)Access Free Blast
Free
Posted in: BCMA, CAR-T Sep 15 | 2023KarMMa-9 Trial Design Disclosed; Plans to Accelerate Cell Therapy Development in Multiple Autoimmune Diseases; Innovative and Diverse Preclinical Pipeline Presented; BMS’s 2023 R&D Day SummaryAccess Free BlastFree
Posted in: BCMA, CAR-T Sep 15 | 2023Carvykti’s T2V Receives an RSI; When Could Abecma and Carvykti Receive a CHMP Positive Opinion? September CHMP HighlightsAccess Free Blast
Free
Posted in: Autologous, BCMA Sep 13 | 20232seventy bio Announces Strategic Restructuring and Pipeline Reprioritization; Abecma’s US Revenue Guidance Lowered; Nick Leschly to Resign as CEO; Company to Expand Strategic Partnership with JW TxAccess Free Blast
Free
Posted in: Autologous Sep 12 | 2023Immatics to Combine its PRAME TCR-Ts with Moderna’s Investigational mRNA Vaccine; Cellares and Lyell Enter into a New Collaboration; Adaptimmune Appoints Karen Chagin as Senior VP of Early Stage DevelopmentAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Sep 12 | 2023Carvykti Appears in the CHMP Agenda; September’s CHMP AgendaAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, CD19 Sep 05 | 2023You May Have Missed: Gilead to Collaborate in the Development of TmCD19-IL18; Celularity Partners with Regeneron; Mustang Bio Presents First Data from MB-106’s Multicenter Trial; Anticipated Enrollment of YTB323's SLE Trial Increased- August 2023 Recap (Blast 2/2)Access Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19, Dual/triple agonist, Topics Sep 01 | 2023You May Have Missed: CARsgen Partners with Moderna; AZ to Collaborate in the Development of a New CAR-T in Solid Tumors; Gilead to Evaluate Novel Dual CAR-T; Poseida and Roche Publish P-CD19CD20-ALLO1’s New Trial; Germany’s G-BA Completes Carvykti's Reimbursement - August 2023 Recap (Blast 1/2)Access Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19, Topics Aug 30 | 2023Thoughts on BMS Joining Cellares’s Technology Adoption Partnership Program to Evaluate the Automated Production of One of Its Key CAR-Ts; Could Cellares’s Cell Shutter Become a Competitive Advantage for BMS?Access Free Blast
Free
Posted in: Allogeneic, CD19 Aug 17 | 2023Precision and Imugene Agree on Terms for the Transfer of Azer-cel; Precision to Deprioritize its Cell Therapy FranchiseAccess Free Blast
Get the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.